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Polyunsaturated fatty acids (PUFAs) are bioactive lipids which modulate inflammation and
immunity. They gained recognition in nutritional therapy and are recommended dietary
supplements. There is a growing body of evidence suggesting the usefulness of PUFAs
in active therapy of various gastrointestinal (GI) diseases. In this review we briefly cover
the systematics of PUFAs and their metabolites, and elaborate on their possible use in
inflammatory bowel disease (IBD), functional gastrointestinal disorders (FGIDs) with focus
on irritable bowel syndrome (IBS), and colorectal cancer (CRC). Each section describes
the latest findings from in vitro and in vivo studies, with reports of clinical interventions
when available.
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INTRODUCTION
Gastroenterology is a rapidly-evolving basic and clinical science that concerns organic and
functional gastrointestinal (GI) disorders. The former include inflammatory, infectious and
neoplastic diseases and the latter embrace conditions characterized by chronic symptoms and the
absence of recognized biochemical or structural explanations.
Inflammatory bowel disease (IBD) has been constricted so far mainly to Europe and US, but
currently emerge also in newly industrialized countries in Asia, Middle East, and South America
(Kaplan, 2015). North America and Europe also remain the leading regions of the occurrence
of functional gastrointestinal disorders (FGIDs), especially irritable bowel syndrome (IBS) (Fox
and Muniraj, 2016). In turn, the incidence and mortality of colorectal cancer (CRC) are high in
developed countries and are rapidly rising in low-income and middle-income populations (Arnold
et al., 2016). Despite an ongoing progress in implementing structured screening in reducing the
prevalence rate and developing new treatments, currently available options are not always effective
and often prompt adverse effects (Favoriti et al., 2016). Hence, we still need new tools of prevention
and therapy.
The aim of this review is to explore the studies on polyunsaturated fatty acids (PUFAs), their
metabolites and derivatives, and relate the findings to the pressing problems of gastroenterology.
The scientific bibliography included in this review was collected from the PubMed and Web of
Science databases. We searched for English language review articles or original research published
up to May 2016, using the following keywords alone or in combination: PUFA, arachidonic
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acid, linoleic acid, eicosapentaenoic acid, docosahexaenoic acid,
fish oil, diet in irritable bowel syndrome, inflammatory bowel
disease, Crohn’s disease, ulcerative colitis, colorectal cancer,
functional gastrointestinal diseases. Clinical trials were searched
using ClinicalTrials.gov database.
SYSTEMATIC OVERVIEW OF PUFAs
A fatty acid (FA) comprises aliphatic hydrocarbon chain with
methyl and carboxyl groups at opposite ends; PUFAs contain
more than one double bond in their structure. There are two
main groups of biologically important long chain PUFAs: n-6
PUFA with their first double bond at C6, counting from the
methyl C, and n-3 PUFAs with first unsaturated bond at C3. The
main representatives of these groups are:
• n-6 PUFAs: linoleic acid (LA, 18:2), arachidonic acid (AA,
20:4),
• n-3 PUFAs: alpha-linolenic acid (ALA, 18:3), eicosapentaenoic
acid (EPA, 19:5) and docosahexaenoic acid (DHA, 22:6).
LA and ALA are referred to as essential FAs, because human body
lacks the enzymes for their synthesis. Both LA and ALA are the
precursors for AA, EPA and DHA, and are of primal biological
importance—both FAs must be thus additionally supplemented
in case of enzymatic defects or lack of dietary ALA or LA.
In humans, diet remains a primary source of DHA and EPA
because the efficacy of transforming ALA to longer n-3 PUFAs
is low and personally variable (Glaser et al., 2010). EPA and
DHA are mostly found in fish, especially salmon, whereas the
most important source of ALA are seed oils derived from
walnuts, chia, perilla, rapeseeds or soybeans. Currently, due to
the suboptimal total PUFAs consumption in most populations,
Abbreviations: 2-AG, 2-arachidonoylglycerol; 12-LO, 12-lipooxygenase; 5,6-EET,
5,6-epoxyeicosatrienoic acid; 5-LO, 5-lipooxygenase; AA, arachidonic acid; AEA,
anandamide; ALA, alpha-linoleic acid; CB, cannabinoid; CD, Crohn‘s disease;
CIC, chronic idiopathic constipation; CLA, conjugated linoleic acid; CNS, central
nervous system; COX, cyclooxygenase; CRC, colorectal cancer; CSLC, cancer
stem like cells; CVD, cardiovascular disease; Cyp450, cytochrome 450; DHA,
docosahexaenoic acid; DMPC, dimyristoylphosphatidylcholine; DP, prostaglandin
D2 receptor; DPA, docosapentaenoic acid; DSS, dextran sulfate sodium; EETs,
epoxyeicosatrienoic acids; ENS, enteric nervous system; EPA, eicosapentaenoic
acid; EPA-FFA, free fatty acid eicosapentaenoic acid; EPIC, European Prospective
Investigation of Cancer; FA, fatty acid; FAAH, fatty acid amide hydrolase; FAD1,
fatty acid desaturase 1; FAP, familial adenomatous polyposis; FDA, Food and Drug
Administration; FGIDs, functional gastrointestinal disorders; GI, gastrointestinal;
GRAS, generally recognized as safe; HETEs, hydroxyeicosatetraenoic acids; HT-
29-EP4, HT-29 human CRC cells with EP4 overexpression; IBD, inflammatory
bowel disease; IBS, irritable bowel syndrome; IBS-A, alternating IBS; IBS-
C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS; ICAM,
intracellular adhesion molecule 1; iNOS, inducible nitric oxide synthase; LA,
linoleic acid; LOX, lipooxygenase; LTB-4, leukotriene B-4 ; LXs, lipoxins;
MPO, myeloperoxidase; NAFLD, non-alcoholic fatty liver disease; NO, nitric
oxide; PBMC, peripheral blood mononuclear cells; PGA1, prostaglandin A1;
PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGH2, prostagandin H2;
PGJ2, prostagandin J2; PGs, prostaglandins; PLA2, phospholipase A2; PUFAs,
polyunsaturated fatty acids; RvD, D-type resolving; RvD1, resolvin D1; Rvs,
resolvins; TNBS, 2,4,6-trinitrobenzene sulfonic acid; TRP, transient receptor
potential; TRPA, TRP subfamily A receptor; TRPV4, transient receptor potential
vanilloid type 4; TXs, thromboxanes; UC, ulcerative colitis; VCAM-1, vascular cell
adhesion protein 1; VEGFR-2, vascular endothelial growth factor receptor 2.
there is a growing awareness and support for regular PUFA
supplementation (González-Rodríguez et al., 2013; Sioen et al.,
2013; Kodentsova et al., 2014).
Physiologically, PUFAs are built into lipid membranes. Once
they are released by phospholipase A2 (PLA2), they undergo
processing to many biologically active signaling molecules
(Gomolka et al., 2011; Maskrey et al., 2013; Capra et al., 2015;
Powell and Rokach, 2015). The most important pathways of
PUFAs metabolism include:
• cyclooxygenases (COXs)–act on both n-3 and n-6
PUFAs, yielding prostaglandins (PGs), prostacyclins and
thromboxanes (TXs); altogether branded prostanoids,
• lipooxygenases (LOXs)–convert AA to lipoxins (LXs) and
leukotrienes (LTs). Together with COXs, LOXs also produce
protectins, marensins, and resolvins (Rvs) from n-3 PUFAs,
• cytochrome 450 (Cyp 450)–catalyzes the conversion of both
n-3 and n-6 PUFAs to epoxyeicosatrienoic acids (EETs).
Along with other enzymes, Cyp450 takes part in the
synthesis of PUFA derivatives, producing biologically active
hydroxyeicosatetraenoic acids (HETEs).
Polyunsaturated fatty acids (PUFAs) can also be processed by
non-enzymatic oxidation, creating isoprostanes, and isofurans
which also display biological activity (Galano et al., 2015; Roy
et al., 2016).
Overall, there is a great variety of PUFAs metabolites which
possess pro- and anti-apoptotic properties, play important roles
in inflammation, modulate the immune responses and probably
affect many yet unknown processes (Figure 1; Masoodi et al.,
2015).
PUFAs in Inflammation
So far, the role of PUFAs in inflammation has been mainly
explained by the action of AA. One of its most important
metabolites are PGs, a heterogenous group of molecules
produced by COX-1 and COX-2. Their common precursor
is prostagandin H2 (PGH2) produced from AA and later
metabolized into downstream metabolites (Félétou et al., 2011).
The main pro-inflammatory one is prostaglandin E2 (PGE2),
produced in large quantities by macrophages and neutrophils in
response to inflammatory stimuli. PGE2 induces fever, increases
vascular permeability and vasodilation, and intensifies pain
and oedema mediated by other inflammatory factors, such as
histamine and bradykinin. It also enhances its own synthesis
and induces production of IL-6 in macrophages. Moreover,
PGE2 also plays a role in inducing immune tolerance in the
intestine, not mediated by IL-10 or T regulatory cells (Stenson,
2014). Interestingly, prostaglandin D2 (PGD2), displays a strong,
purely anti-inflammatory effect (Stenson, 2014) acting through
two types of prostaglandin D2 receptors (DP), DP1 and DP2,
the latter being identified as a member of the chemokine
receptor family (Félétou et al., 2011). Can also be dehydrated to
produce prostagandin J2 (PGJ2), involved in the differentiation
of adipocytes by activation of PPARγ nuclear receptor (Félétou
et al., 2011).
Besides PGs, the main AA metabolites are thromboxane A2
(TxA2), leukotriene B4 (LTB4) and LXs. TxA2 mainly promotes
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FIGURE 1 | Derivatives of polyunsaturated fatty acids (PUFA) with anti-
and pro-inflammatory properties. In contrast to n-3 PUFA-derived
mediators, which are mostly considered as anti-inflammatory, n-6 PUFA
derivatives promote inflammatory response. However, one of the unique
metabolites of n-6 PUFA are lipoxins (Lx)- LxB4 and LxB5, which display a
wide spectrum of anti-inflammatory and pro-resolution actions. AA,
arachidonic acid; AEA, N-arachidonoylethanolamide, anandamide; ALA,
alpha-linoleic acid; 2-AG, 2-arachidonoylglycerol; DHA, docosahexaenoic
acid; EPA, eicosapentaenoic acid; FA, fatty acid; LOX, lipoxygenases; LTB-4,
leukotriene B-4; LxA4, lipoxin A4; LxB4, lipoxin B4; PGD2, prostaglandin D2;
PGE2, prostaglandin E2; TxA2, thromboxane A2; 12/15 HETE, 12/15
hydroxyeicosatetraenoic acid.
platelet aggregation and vasoconstriction but is also reportedly
involved in allergies, modulation of acquired immunity,
atherogenesis, neovascularization, and metastasis of cancer cells
(Félétou et al., 2011). LTB4, in turn, recruits neutrophils,
promotes vascular leakage, and regulates epithelial barrier
function (Cornejo-García et al., 2016), whereas LXs diminish the
inflammatory process by limiting leukocyte infiltration (Maderna
and Godson, 2009). This shows that n-6 derivatives can both
exacerbate and resolve inflammation. In contrast, n-3 PUFAs are
considered purely anti-inflammatory FAs, because they serve as
substrates for PLA2 in lipid membranes. This causes reduction
in AA-derived pro-inflammatory cytokines and suppresses the
inflammatory process (Okada-Iwabu et al., 2013).
Nevertheless, PUFAs metabolites gather increasing
recognition as prime drivers of inflammation and its
resolution. For example, 12-lipooxygenase (12-LO) plays a
role in atherosclerosis and adipose tissue inflammation in obesity
(Masoodi et al., 2015). In a rat model of obesity, Chakrabarti et al.
(2011) reported increased expression of 5- and 12-LO in visceral
adipocytes, along with increased amounts of their products: 12-
and 5- HETE, and LTB-4.
In addition to pro- and anti-inflammatory properties
of PUFAs derivatives, they can also exhibit pro-resolution
effects. Contrary to well-established beliefs, resolution of
inflammation is also an active process rather than simple
cessation of inflammatory stimuli (Shinohara and Serhan,
2016). It is mediated by specialized pro-resolving molecules
(LXs, Rvs, protectins, and maresins) derived from n-3 PUFAs,
mainly EPA and DHA (Serhan, 2014). All these molecules
mitigate neutrophil influx, stimulate phagocytosis and enhance
efferocytosis of cellular debris. Additionally, they also exert class-
specific influence on inflammation processes; they counteract
eicosanoids, chemokines, and cytokines, regulate specific micro
RNAs and act in a receptor-specific manner on human
neutrophils and macrophages. In line, administration of RvD1
and 17-hydroxy-DHA to obese diabetic mice not only improved
insulin sensitivity but also reduced levels of inflammatory
cytokines in WAT and decreased its infiltration by macrophages.
Importantly, pro-resolving molecules stimulate heme oxygenase
system to produce low concentrations of carbon oxide which acts
protectively for tissues (Shinohara and Serhan, 2016).
Another example of signaling molecules involved in
inflammatory pathways are endocannabinoids, a heterogeneous
group of lipid mediators acting on classical and non-classical
cannabinoid (CB) receptors. Two very important representatives
of these ligands are N-arachidonoylethanolamine named
anandamide (AEA), and 2-arachidonoylglycerol (2-AG), both
derivatives of AA (Alhouayek and Muccioli, 2012). Both
suppress mast cells activation, decrease the production of
macrophages and pro-inflammatory cytokines, and modulate
T-cell helper activity. Moreover, endocannabinoids play an
important role in GI-related inflammation. In line, the activation
of classical CB1 and CB2 receptors reduces inflammation-
induced hypermotility and attenuates visceral hypersensitivity
(Sanson et al., 2006). In colonic cell lines, endocannabinoids
promote wound closure, thus becoming an attractive target
for treating IBD-related lesions (Alhouayek and Muccioli,
2012).
Overall, PUFAs offer many ways to modulate inflammation.
They have also been linked with IBD on an epidemiological level.
Analysis of the European Prospective Investigation of Cancer
(EPIC)-Norfolk cohort (N = 25639) found a positive association
of dietary AA intake with ulcerative colitis (UC) incidence and a
protective effect of oleic acid intake (de Silva et al., 2014).
PUFAs IN INFLAMMATORY BOWEL
DISEASES
Inflammation is a biological response that occurs in many
GI disorders and simultaneously underlies both “classical”
diseases, such as non-alcoholic fatty liver disease (NAFLD)
and non-specific IBD including UC and Crohn’s disease (CD).
NAFLD is characterized by a cryptic low-grade inflammation
process affecting the liver, with concomitant features of
metabolic syndrome: obesity, dyslipidemia, insulin resistance and
hypertension (Xu et al., 2015; Yki-järvinen, 2015). NAFLD affects
patient’s lifespan by elevating the risk of cardiovascular disease
(CVD) (Xu et al., 2015; Yki-järvinen, 2015). The symptoms
of NAFLD are usually scarce and the treatment is mainly
symptomatic—it includes losing weight, increase in physical
activity and diet modifications (Yki-järvinen, 2015). n-3 PUFAs
are considered a relevant supplementation in patients with
hypertriglyceridemia and many studies suggest the important
role of PUFAs inNAFLDpathophysiology (Gambino et al., 2016).
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However, there is no consensus from human trials for their
systematic use as a drug treatment (Boyraz, 2015; Nakamoto
et al., 2016). Nevertheless, this aspect is not the subject of this
review; for detailed information please see (Boyraz, 2015; Yki-
järvinen, 2015; Musso et al., 2016).
In contrast to NAFLD, the symptoms of UC and CD are
very pronounced and significantly affect patient‘s quality of
life (Sobczak et al., 2014). The most common symptoms are
diarrhea, fever and fatigue, abdominal pain and cramping,
intestinal bleeding, reduced appetite and unintended weight loss.
Their core is a constant, low-grade inflammation with temporary
exacerbations. Both UC and CD affect 37 adults and 5-11
children per 100 000 annually, leading to increased mortality
(Ananthakrishnan, 2015; Ye et al., 2015). The pathogenesis of
IBD is not completely defined, but recently the spotlight is on
microbiota-stimulated immunoreactivity and adipose tissue
hormonal dysregulation (Kostic et al., 2014; Schaubeck and
Haller, 2015). What is more important, the currently available
treatment includes 5-aminosalicylates, steroids, biological
therapy and surgical procedures—all aggressive and with
significant side effects (George et al., 2015; Khanna and Feagan,
2015; Meyer et al., 2015). Thus, it is crucial to seek new agents
that could influence the clinical course of IBD and alleviate or
prevent exacerbations. In this field, PUFAs are recognized as
promising agents.
Animal Studies
The impact of PUFAs on colitis-associated inflammation has
been extensively studied in animal models (Huang et al., 2016).
To date, oral administration of dextran sulfate sodium (DSS)
and intracolonic administration of 2,4,6-trinitrobenzenesulfonic
acid (TNBS) dissolved in ethanol are two most widely used
models to induce UC and CD, respectively (Scheiffele and Fuss,
2002; Chassaing et al., 2014; Sałaga et al., 2014a,c; Salaga et al.,
2016). The main difference between these two models of colitis
is that DSS directly damages gut epithelial cells of the basal
crypts and disrupts the integrity of the mucosal barrier, whereas
in TNBS model, ethanol breaks mucosal barrier and therefore
allows TNBS to haptenize colonic proteins in order to stimulate
the immune response.
One of the first targets in fighting inflammation may be
conjugated LA (CLA) (Viladomiu et al., 2013). Themixture of LA
isomers has been categorized by Food and Drug Administration
(FDA) as “generally recognized as safe” (GRAS) and can be used
as a supplement. In pig models of colitis, CLA was proved to
downregulate inflammation by lowering serum levels of tumor
necrosis factor alpha (TNF-α) and nuclear factor κB (NF-κB)
while increasing levels of transforming growth factor β (TGF-β)
and upregulating the expression of peroxisome proliferator-
activated receptor γ (PPAR-γ) (Hontecillas et al., 2002). These
findings were confirmed inDSS- and CD4-induced colitis inmice
(Bassaganya-Riera et al., 2004).
Another idea of curbing colonic inflammation is to utilize
n-3 PUFAs. This is based on the observation that transgenic
mice with inborn ability to convert n-6 PUFA to n-3 PUFA
were protected from experimental colitis. Furthermore, in a rat
model of TNBS-induced colitis, diet supplemented with ALA
decreased the number of lesions, normalized colon induced NO
synthase (iNOS) and COX-2 expression and lowered levels of
TNF-α and leukotriene B-4 (LTB-4) to baseline (Hassan et al.,
2010). However, it had no effect on PGE2 level and, more
importantly, it did not lower the disease inflammation score
(Hassan et al., 2010). In TNBS model, ALA supplementation
was also proved to decrease the levels of intercellular adhesion
molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-
1) and vascular endothelial growth factor receptor 2 (VEGFR-
2), thus suppressing the angiogenic component of inflammation
(Ibrahim et al., 2012).
Other studies concentrate on n-6 to n-3 PUFAs ratio rather
than one particular FA. An increase in western high-fat diet
consumption worldwide results in dramatic changes in this ratio
of FAs from 2:1 in the past, to 10:1 nowadays (Tyagi et al.,
2012). In DSS-induced colitis replacement of dietary LA with
ALA, and therefore decreasing LA/ALA ratio to 2:1, reduced
the severity of colitis and significantly mitigated inflammation,
when measured indirectly as shortening of the colon (Tyagi et al.,
2012). This change was probably caused by decreased neutrophil
infiltration into the colonic tissue, probed by the decrease
in myeloperoxidase (MPO) and colonic alkaline phosphatase
activity. Supplementation with ALA also prevented the rise in
TNF-α and IL-1β levels, when compared to the control group.
Moreover, this diet also partially decreased plasma NO and
completely prevented the rise in radical stress in colonic tissue. A
reduction in histological score of inflammation was also observed
(Tyagi et al., 2012).
Another way to modulate inflammation is to use specific
PUFAs metabolites rather than primary FAs. Given the fact
that adipose tissue inflammation plays an important role in
CD (Michalak et al., 2016), these metabolites may be actively
used to suppress existing inflammation or prolong remission
in those patients. EPA- and DHA-derived specialized pro-
resolving mediators are prime candidates for animal and clinical
trials.
A double role of PGE2 in inflammation has also been
demonstrated in animals. In DSS-induced colitis PGE2 enhanced
proliferation and epithelial healing, whereas in TNBS-induced
colitis it promoted Th17 differentiation pathway in lymphocytes
and thus exacerbated inflammation (Stenson, 2014). These
seemingly inconsistent actions of PGE2 may result from
profound biological differences in DSS- and TNBS-induced
colitis.
Another group of PUFAs derivatives tested in animal models
of IBD are agents targeting the endocannabinoid system. Firstly,
it has been demonstrated that CB1- and CB2-knockout mice
show increased susceptibility to DSS-induced colitis (Alhouayek
and Muccioli, 2012). In line, administration of cannabinoids
or inhibitors of cannabinoid degradation decreased intestinal
motility, peristalsis and colonic propulsion in rodents in a CB1-
dependant manner (Alhouayek and Muccioli, 2012). Sałaga et al.
(2014c) thoroughly tested fatty acid amide hydrolase (FAAH)
inhibitor in TNBS- and DSS-induced colitis. In the TNBS
model, orally administered FAAH inhibitor exerted potent anti-
inflammatory effect which improved total histological score and
decreased tissue MPO activity. Such changes were not observed
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in the DSSmodel, probably due to differentmechanisms involved
in the inflammatory process (Sałaga et al., 2014b,c).
When assessing possible use of PUFAs in therapy, it
may be worth to also consider alternative ways of delivery.
One of the newest methods includes the encapsulation of
n-3 PUFA in liposomes. Notably, by adding radioactive,
fluorescent or superparamagnetic agents it is possible to track
the drug distribution in the organism and better study its
local actions (Calle et al., 2015). Liposomes were already
tested in DSS-induced colitis medium, which serves to deliver
glucocorticosteroids; unfortunately, this therapy led to worsening
of fecal blood loss (Crielaard et al., 2011). However, when
imbued with n-3 PUFA, liposomes demonstrated a clear
anti-inflammatory effect in DSS-induced colitis in mice and
exerted important anti-tumoral effects against glioma. Imaging
techniques confirmed the presence of magnetoliposomes in
inflamed regions, which opens up many possibilities for targeted,
image-guided delivery of medical agents, which may find
application in IBD therapy (Calle et al., 2015).
The last study that needs to be mentioned in this chapter
may be considered as a bridge toward clinical trials. Meister and
Ghosh (2005) incubated biopsies from IBD patients with fish
oil and found reduced inflammation manifested by a rise in IL-
1a/IL-1b ratio in tissues obtained from UC, but not from CD
patients. These outcomes indicate differences in a diet that should
be taken into consideration while composing nutritional therapy
for UC or CD patients.
Clinical Application
Despite promising results in animal studies, translation of
PUFA-based interventions into humans is difficult. One of
the attempts was to utilize PUFAs against chronic low-
grade inflammation in obesity. It has been demonstrated that
obesogenic diet concomitant with EPA/DHA supplementation
resulted in a more favorable metabolic profile and normalized
the levels of endogenous Rvs and protectins, attenuated adipose
tissue inflammation and improved insulin sensitivity (Minihane
et al., 2015). Another study proved that high dose of long-
chain n-3 PUFA, delivered to severely obese non-diabetic
patients, increased secretion of anti-inflammatory eicosanoids
and decreased expression of inflammatory genes in subcutaneous
adipose tissue Finally, a systematic review by Rangel-Huerta
et al. (2012) reported that n-3 PUFAs supplementation affects
inflammatory biomarkers in cardiovascular disease and chronic
and acute conditions. However, its effects varied in disease-
specific manner.
Polyunsaturated fatty acids (PUFAs) have also been evaluated
as a factor involved in the course of IBD. Total dietary intake of
PUFAs has been shown to positively correlate with the risk of UC,
although with marginal significance and without distinguishing
between n-3 and n-6 PUFA (Hart et al., 2008). A more detailed
big cohort study demonstrated that total dietary n-3 PUFAs,
particularly EPA and DHA, protected from UC development
in patients older than 45 years (John et al., 2010). Finally,
a large prospective cohort study in women also proved the
association between higher intake of dietary long chain n-3
PUFAs and a reduced risk of UC (Ananthakrishnan et al., 2014).
Noteworthy, the latest case-control trial reported that dietary
intake of fats, especially PUFAs, is associated with increased risk
of UC; however, no positive association was seen specifically
for n-3 PUFAs intake (Rashvand et al., 2015). Altogether, the
above-mentioned studies suggest that n-6 PUFAs facilitate the
development of UC while n-3 PUFAs possibly prevent it. This
leads to assumption that n-3 PUFAs could be utilized either
in inducing or prolonging remission in IBD. Important clinical
trials together with summary meta-analysis have been listed in
Table 1.
In patients with an active form of IBD, administration of
duodenal seal oil significantly reduced disease activity index,
normalized n-3/n-6 PUFAs ratio and alleviated pain, especially
joint-related pain (Arslan et al., 2002; Bjørkkjær et al., 2006).
Worth mentioning, in patients with mild to moderate CD, the
supplementation with CLA suppressed the ability of T-cells to
produce TNF-α, IFN-γ, and IL-17, which decreased disease
activity and improved the quality of life of patients (Viladomiu
et al., 2013).
When joined with antioxidants, n-3 PUFAs supplementation
altered the composition and function of peripheral blood
mononuclear cells (PBMCs). Consequently, when stimulated
with mitogens, PBMCs produced less IFN-γ, but when
stimulated by lipopolysaccharide generated less PGE2 (Trebble
et al., 2004).
Possible clinical application of PUFAs has been assessed
by a few systematic reviews and meta-analyses. The study
by Turner et al. (2011) evaluated the effectiveness of n-3
PUFAs in maintaining remission in patients with IBD. They
found moderate but significant beneficial effect of omega FA
supplementation in patients with CD (relative risk 0.77; 95%
confidence interval 0.61–0.98) (Turner et al., 2011). However,
conclusions were drawn from only 6 trials comprising 1039
patients altogether, with probably high heterogeneity and
publication bias. Analysis of 3 trials on supplementation in 138
patients with UC did not report any significant effect. The same
or similar analysis was probably republished in 2014 concluding
that n-3 PUFAs may be ineffective for maintenance of remission
in CD (Lev-Tzion et al., 2014).
Another systematic review published in 2012 confirmed
ineffectiveness of n-3 PUFA supplementation in remission
phase of UC or CD. Nonetheless, the supplementation showed
many beneficial effects in patients with active phase of UC.
Unfortunately, due to high variability of studies and high number
of parameters assessed, these results could not be unified (Cabré
et al., 2012).
The reason for the shortcomings of the intervention trials
may be related to different doses applied in each study and
complex interfering metabolic reactions that PUFAs undergo
before exerting their biological effects. The key to unlock its
power is to utilize alternative, effective ways of drug delivery, such
as liposomes. This would allow to evaluate the effects of EPA or
DHA action in specific inflammatory environment and thus open
up endless possibilities of using particular n-3 PUFA metabolites
to achieve more specific effects.
n-3 PUFAs supplementation may also be an attractive option
in pediatric patients. In children with CD receiving mesalazine,
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TABLE 1 | Clinical trials investigating the use of n-3 PUFAs in IBD.
Condition Study design Participants Intervention Outcomes References
IBD-related joint pain RCT (10 d. treatment period) 17 (9 CD, 10 UC) Seal oil (n = 10) vs. soy oil (n = 9)
10ml 3x daily, administered
duodenally
Reduced bodily pain Bjørkkjær et al., 2006
Active CD Open label (12 weeks of
treatment)
13 CLA 6 g/d Drop in CD activity
index, increase in
quality of life
Bassaganya-Riera
et al., 2004
CD (patients with currently
or recently raised
inflammatory markers)
RCT (24 weeks of treatment) 61 EPA and DHA (+ antioxidants) 2.7
g/d for (n = 31), Placebo (n = 30)
reduction in IFNγ
production by
mitogen-stimulated
PBMC
Trebble et al., 2004
Pediatric patients with CD
in remission
Double-blind RCT (12
months of treatment)
38 5 ASA (50 mg/kg/d) + EPA + DHA
(3 g/d) vs. 5-ASA (50mg/kg/d) +
olive oil (3 g/d)
Lower relapse rate
after 1 year
Romano et al., 2005
Active CD Double-blind RTC (9 weeks
of treatment)
31 Nutritional treatment with an
isocaloric diet Impact Powder (3 g
omega-3 FA, 11.4 g L-Arginine, and
1.2 g RNA per day) Control formula:
Nutritional supplement with 7.8 g
linoleic acid per day (all patients
received systemic steroid therapy)
Significant decrease
in CDAI and
C-reactive protein in
both groups (no
difference)
Nielsen et al., 2005
Active UC Double-blind RTC (6
months of treatment)
121 (86 completed
the protocol)
Nutritional supplement with <2.5 g
EPA and <1.0 g DHA per day vs.
supplement based on sucrose alone
(Steroids and 5-ASA allowed, their
doses adjusted to clinical response)
Similar clinical
improvement, but
faster reduction in
steroid dose in active
group
Seinder et al., 2005
Newly-diagnosed
pediatric patients with CD
Double-blind RTC (6 weeks
of treatment)
41 Polymeric diet with 1.5% of energy
as ALA and 3% as LA vs. elemental
diet with 0.4% of energy ALA and
5.4% as LA (No other active therapy
for CD allowed)
Similar remission rate
between the groups
Grogan et al., 2012
CD patients immediately
after reaching remission
Double-blind RTC (58
weeks of treatment)
375 Enteric coated capsules (2-2.4 g
EPA/day and 0.6–1 g DHA/day) vs.
placebo capsules
47.8% relapse rate
vs. 48.8% in placebo
Feagan et al., 2008
CD patients in remission Double-blind RTC (52
weeks of treatment)
363 Enteric coated capsules (2–2.4 g
EPA/day and 0.6–1 g DHA/day) vs.
placebo capsules
31.6% relapse rate
vs. 35.7% in placebo
group
Feagan et al., 2008
CD patients in remission Metaanalysis of RCT (at
least 6 months of treatment)
1039 Fish oil or n-3 PUFA Predefined
doses
Risk of relapse - RR
0.77, 95% CI 0.61 to
0.98
Turner et al., 2011
Lev-Tzion et al., 2014
Cabré et al., 2012
ASA, amino salicylic acid; CD, Crohn disease; CLA, conjugated linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; IBD, inflammatory bowel disease; IFNγ ,
interferon-gamma; PUFA, polyunsaturated fatty acid; RCT, randomized controlled trial.
supplementation with triglyceride form of n-3 PUFAs in gastro-
resistant capsules, containing 400 mg/g of EPA and 200 mg/g
of DHA, significantly lowered the relapse rate within 1-year
observation with respect to patients supplemented with olive oil
placebo capsules (Romano et al., 2005).
Currently, there is no strong evidence that oral n-3 PUFAs
supplementation significantly changes the course of either CD
or UC, enabling clinicians to drop steroid or 5-ASA therapy.
However, n-3 PUFAs may be valuable additions to standard
treatment, but more uniformly-devised studies are warranted.
PUFAs IN IRRITABLE BOWEL SYNDROME
Dietary fat also plays an important role in FGIDs (Feinle-
Bisset and Azpiroz, 2013). This heterogenous group is generally
defined as conditions with a variable combination of chronic or
recurrent GI symptoms. Irritable bowel syndrome (IBS) is the
most prevalent FGID noted in the general population, which
constitutes 25–50% of gastroenterology outpatients’ workload
(Wilson et al., 2004). According to the Rome IV criteria, a
symptom-based classification system, the clinical symptoms of
IBS include abdominal pain, bloating, stool irregularities with
concomitant psychiatric and somatic comorbidities (Drossman
et al., 2010; Palsson et al., 2016). Depending on the pattern of
symptoms, IBS may be classified as diarrhea-predominant IBS
(IBS-D), constipation-predominant IBS (IBS-C) or alternating
IBS (IBS-A). Among others, one of the putative theories that
underlie IBS development is the imbalance within the brain-
gut axis, made up of the enteric nervous system (ENS), central
nervous system (CNS), and the hypothalamo-pituitary-adrenal
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axis (Fichna and Storr, 2012). Such imbalance may be triggered
by early life stress, which predisposes to develop stress
related disorders, including IBS later in life. A number of
studies reported low-grade inflammation as another mechanism
implicated in IBS, in which higher infiltration of cytokines e.g.,
IL-4, IL-6, or TNF-α, pro-inflammatory mediators and mast cells
in the colonic mucosa impairs the tight junctions complexity and
thus exacerbates IBS symptoms (Camilleri et al., 2012).
The management of IBS requires multimodal approach,
including pharmacological, psychological, as well as
complementary and alternative medicines. Approved and
investigated therapeutics are summarized in Table 2.
Currently, dietary interventions are gaining much attention
(Böhn et al., 2013; Cuomo et al., 2014). In line, a diet excluding
foods high in short-chain carbohydrates termed FODMAPs
(Fermentable Oligo-, Di- and Monosaccharides and Polyols) has
proven its effectiveness in alleviating IBS symptoms. More recent
evidence also indicates the usefulness of dietary lipids (Caldarella
et al., 2005; Solakivi et al., 2011; Halmos et al., 2014).
Animal Studies
Visceral hypersensitivity can be mimicked in animal model
of IBS. Rats, when separated as neonates from their mother
and exposed in later life to acute stress (e.g., in the water
avoidance test) display hypersensitivity to mechanical colorectal
distension that can be measured electromyographically, and
manifest increase in visceral pain. In these animals, elevated levels
of pro-inflammatory PUFAs were reported (Clarke et al., 2009).
However, in maternally separated rats, dietary supplementation
with fish oil reduces neither the response to colon distension nor
the level of pro-inflammatory cytokines in colonic tissue (van
Diest et al., 2015). Another study combined the supplementation
with CLA and probiotics (B.breveDPC6330) (Barrett et al., 2012).
Groups of 15 rats were either separated from their mothers or
not, and fed with probiotic, probiotic together with LA and ALA,
or placebo. The supplementation provided significant changes in
lipid composition in the rats’ serum, colonic tissue and prefrontal
cortex, but failed to clearly change the colonic hypersensitivity
measured by colon distension (Barrett et al., 2012). Of note,
the use of human intestine bacteria (B. breve, strain DPC6330)
affected the FA metabolism in maternally separated rats to a
greater extent than in non-separated animals. The study thus
supports the hypothesis that changes in the gut microbiota
alter host lipid (e.g., palmitoleic acid, DHA or propionate)
composition, and are responsible for the occurrence of IBS
symptoms.
Clinical Application
Polyunsaturated fatty acids (PUFAs) can modulate mast cells
activity and further mitigate visceral hypersensitivity, a prime
feature of IBS. This leads to the question whether supplementing
PUFAs could help change the clinical course of IBS and improve
patients quality of life. The study by Clarke et al. (2010) reported
significant increase in the level of AA and its metabolites
in serum samples from IBS patients, compared with healthy
controls. An elevated concentration of LTB4 was found across
all IBS subtypes, whereas PGE2 showed type-specific elevation
associated solely with IBS-D. It should be noted that PGE2 is
able to cross the blood brain barrier, which links FA metabolism
and inflammation to brain-gut axis, and therefore may be
implicated in the course of IBS (Clarke et al., 2010). There was
no correlation between the plasma level of AA and symptom
severity. Surprisingly, the same study also found increased
concentrations of n-3 PUFAs in serum of IBS patients, however
the underlying cause of this augmentation remains unexplained
(Clarke et al., 2010).
Polyunsaturated fatty acids (PUFAs) metabolites can bind
TRP ion channels, such as transient receptor potential vanilloid 1
(TRPV1), TRPV4, and TRP subfamily A receptor 1 (TRPA1), and
signal to sensory neurons to evoke hypersensitivity symptoms
seen in IBS. The levels of TRP agonists differ between colon
biopsies from IBS patients and healthy individuals. Cenac
et al. (2015) demonstrated an increased concentration of a
TRPV4 agonist, 5,6-epoxyeicosatrienoic acid (5,6-EET), but
not TRPA1 and TRPV4 agonists, in colonic biopsies from
IBS-D patients, when compared with control group. This
augmentation in 5,6-EET was positively correlated to pain
severity and bloating. Biopsies from both IBS-C and IBS-
D patients showed elevated levels of PGE-2 and decreased
concentration of a TRPV1 agonist. Modulating TRP activity by
PUFAs or PUFAs-based ligands may potentiate the production
of TRPV4 and its agonist and thus modulate visceral sensation
in IBS.
The same study proved that intracolonic administration of
supernatants from IBS-D patients’ colonic biopsies to mice led
to development of hypersensitivity (manifesting as allodynia and
hyperalgesia) and increased 5,6-EET, PGE-2 and 15-HETE levels
in mouse colonic tissues (Cenac et al., 2015). These changes
were prevented by using TRPV4 knockouts or pretreating mice
with TRPV4 inhibitors. Finally, the study proved that 5,6-
EET stimulates colonic neurons by acting on their TRPV4; the
same effect was achieved later with bioptic supernatants from
IBS-D patients and hypersensitive mice. The study highlights
the potential of PUFA-based therapies in targeting TRPV4
channels.
Currently, there are no clinical trials assessing effects of PUFAs
supplementation on clinical course of IBS. Such studies are
warranted given the recently-revealed inflammatory factor in
IBS.
Apart from supplementation, PUFAs may also serve as base
for devising new biologically active agents. Of note, lubiprostone,
a PGE1 derivative, has been registered in the treatment of IBS-C
and chronic idiopathic constipation (CIC). It activates type 2
chloride channels in apical membrane of intestinal epithelium
and thus increases fluid secretion in the GI tract (Li et al.,
2016). Lubiprostone also promotes repair of epithelial barrier
(Cuppoletti et al., 2012). Most recent metaanalysis by Li et al.
(2016) confirmed the effectiveness and safety of lubiprostone
in diminishing the severity of constipation and improving
stool consistency, degree of abdominal pain and discomfort.
Compared to alternative therapies, patients on lubiprostone
have improved health-related quality of life, symptom control,
reduced symptoms severity and are more satisfied with their
therapy (Solem et al., 2016).
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TABLE 2 | Currently available and emerging pharmacological treatment options for IBS-C and IBS-D (Sweetser et al., 2009; Chey et al., 2011; Mozaffari
et al., 2013; Mosinska et al., 2015, 2016; Shailubhai et al., 2015).
Drug class Generic name Mechanism of action Indication ClinicalTrials.gov Identifier
BA modulators Elobixibat IBAT inhibitor IBS-C NCT01833065
NaCDC BA analog IBS-C NCT00912301
Prokinetics Itopride ACh esterase inhibitor; D2 receptor antagonist IBS-C NCT01027260
Relenopride 5-HT4 partial agonist IBS-C NCT02082457
Mosapride 5-HT4 agonist IBS-C NCT01505777
Tegaserod approved
Velusetrag NCT00391820
Renzapride 5HT4 agonist and 5HT2b and 5HT3 antagonist IBS-C NCT00268879
Pumosetrag 5-HT3 agonist IBS-C not available
Alosetron 5-HT3 antagonist IBS-D NCT00067457
Ondansetron not available
Ramosetron approved in Japan, Korea and Thailand
PAMORA Loperamide µ-opioid receptor agonist IBS-C approved
Eluxadoline µ-opioid receptor agonist, δ-opioid receptor antagonist IBS-D approved
Secretagogue Dolcantide GC-C agonist IBS-C not available
Linaclotide approved in USA, EU
Plecanatide NCT01722318
Lubiprostone CIC2 activator IBS-C approved in USA
AGENTS WITH OTHER MECHANISMS OF ACTION
TC6499 Alpha3beta4 NNRs modulator IBS-C NCT01149200
Taranabant CB1 receptor agonist IBS-C not available
Crofelemer Chloride channel inhibitor IBS-D NCT00461526
Pexacerfont CRF receptor antagonist IBS-D NCT00399438
ROSE-010 GLP-1 Analog IBS-C NCT01056107
TU-100 Kampo medicine IBS-C NCT01890837
Asimadoline κ- opioid agonist IBS-D NCT01100684
Ibodutant NK2 antagonist IBS-D NCT01303224
NHE3 inhibitor Tenapanor IBS-C NCT02727751
PUFAs IN COLORECTAL CANCER
Colorectal cancer (CRC) is the third most common cancer
both in men and women, and second in cancer-related deaths
(Yan et al., 2016). The risk of CRC is strongly affected by
environmental modifiable factors, such as exercise or dietary
habits (Teixeira et al., 2014). Fatty acid intake with focus on
n-3 PUFAs is one of the main candidate factors affecting CRC
incidence and clinical course. It is generally accepted that n-3
PUFAs are associated with protection from CRC, and n-6 PUFAs
with its promotion. However, there is a limited number of studies
undermining this paradigm and suggesting a more complicated
role of PUFAs (Zhang et al., 2015b).
Primary Prevention
The primary prevention studies yield mixed results. A large 2 ×
2 factorial study showed no association between the therapy with
insulin glargine or supplementation with n-3 PUFAs and CRC
incidence rate (Bordeleau et al., 2014). Similarly, metaanalysis by
Shen et al. (2012) did not reveal any significant impact of n-3
PUFAs intake on CRC risk in general. Importantly, the subgroup
analysis revealed a significantly reduced risk of CRC among
men but this aspect needs further investigation (Shen et al.,
2012). In contrast, metaanalyses of prospective cohort studies
that investigated the impact of fish consumption or n-3 FAs on
CRC prevalence andmortality, provided evidence that fish intake
(at least once per week) inhibits CRC carcinogenesis and can
lower risk of CRC for about 4% (Park et al., 2013).
On the other hand, PUFAs can still be used as adjuvant agents
in therapy or as prevention in high-risk groups, for example in
patients with familial adenomatous polyposis, or as a secondary
prevention.
Colon Cancer Cell Lines
In human CRC cell lines, n-3 PUFAs modulate both p53-
dependent and independent pathways, inhibit COX2 pathway,
suppress NF-κβ and downregulate Bcl-2 expression suggesting
its anti-proliferative and pro-apoptotic properties (Collett et al.,
2001; Sala-Vila et al., 2010; Eltweri et al., 2016). The action of
PUFAs on CRC cells is mediated by mitochondrial-dependent
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pathways and varies with a degree of cell differentiation. Zhang
et al. (2015a) demonstrated that both n-3 and n-6 PUFAs induced
apoptosis in LoVo and RKO CRC cell lines when applied at
concentrations above 120µM (tested at 0-200µM). The pro-
apoptotic effect of PUFAs is greater in semi-differentiated RKO
line compared with undifferentiated LoVo cells. Furthermore,
DHA and to lesser extent EPA, enhanced the effects of
radiotherapy in two human CRC cell lines (Cai et al., 2014).
Another study by De Carlo et al. (2013) investigated cell-
specific action of n-3 PUFAs on differentiated tumor cells and
cancer stem like cells (CSLC). The treatment decreased the
expression of CD133 in CD133+ colon CSLCs, what suggests
a differentiation-stimulating effect (De Carlo et al., 2013).
Moreover, EPA also sensitized CRC cells to chemotherapeutics,
5-fluorouracyl, and oxaliplatin. An increased sensitivity to 5-
fluorouracyl was found in CSLCs (De Carlo et al., 2013). Another
study demonstrated that EPA coupled with these two cytostatics
inhibits cell growth, colonosphere formation, sphere-forming
frequency and increases the sphere disintegration in otherwise
resistant cells (Vasudevan et al., 2014). Similar synergistic
interaction of n-3 PUFAs with chemotherapeutic agents was
also supported by other authors; for more information, please
see: (Jordan and Stein, 2003; Cai et al., 2014; Eltweri et al.,
2016). Currently, 5-fluorouracyl and oxaliplatin are first line
of treatment in CRC and EPA might be considered a valuable
addition. However, clinical trials are needed to determine if the
sensitizing effect of EPA is present and clinically relevant in vivo.
Additionally, PUFAs also modulate the inflammatory
environment in CRC patients. The serum level of n-6 C20:4
PUFAs show positive association with IL-6 and inverse with levels
of metalloproteinase-7. In line, there is a positive correlation
between C22:5 n-3 PUFAs and IFN-γ, inverse association
between C20:5 n-3 PUFA and metalloproteinase-2 and C22:6
n-3 PUFA and levels of IL-8 and metalloproteinase-9 (Jia et al.,
2016). This suggests that nutritional intervention may influence
the inflammatory signaling and clinical course of CRC.
Animal Models
The in vivo results are consistent with in vitro studies. In
mice and rats, EPA and DHA supplementation reduces cell
proliferation and promotes apoptosis (Gutt et al., 2007). This
inhibits liver metastasis and leads to decrease in the tumor
volume. Importantly, hybrid liposomes (HLs) including PUFAs
have demonstrated an inhibitory effect on the growth of tumor
cells both in vitro and in vivo (Ichihara et al., 2014). Tanaka et al.
(2008) demonstrated that HLs enriched with n-3, n-6, and n-9
PUFAs inhibit the growth of tumor cells, including colon tumor
(WiDr) cells in vitro. The highest inhibitory effect was seen in
HLs enriched with n-3 PUFA DHA; this action could be attained
mostly by increased peroxidation and further necrosis of the cell.
However, the effect of DHA-HLs was not totally prevented by
addition of antioxidant so their mechanism of action is likely to
be more complicated, especially that DHA also demonstrated a
pro-apoptotic effect in WiDr colon tumor cells (Tanaka et al.,
2008).
More recently, Ichihara et al. reported therapeutic effects
of cationic HLs on the hepatic metastases of CRC along
with apoptosis in mice. Female mice with severe combined
immunodeficiency were injected intrasplenically with HCT116
cells (5.0 × 106 cells). They were then randomized for
intravenous administration of liposomes, containing either L-α-
dimyristoylphosphatidylcholine (DMPC) (136 mg/kg/d) or 50%
molar DHA (65.7 mg/kg/d) and 50% molar DMPC. After 14
days of therapy, a significant improvement in median survival
time and induction of apoptosis in liver metastases were observed
(Ichihara et al., 2014).
It is possible that liposome-delivered PUFAs may exert more
potent effects on cancer cells than its oral administration;
however, this needs further testing and clinical trials. Currently,
only orally-supplemented PUFAs are available, but their various
forms differ in the efficacy of their absorption from the intestine
and incorporation into cells. The EPA in the free fatty acid
(EPA-FFA) form is absorbed better from small intestine than the
ethyl ester or triglyceride form (Lawson and Hughes, 1988). In
vitro, EPA-FFA induces apoptosis of HCA-7 human CRC cells
by decreasing PGE2 and increasing PGE3 synthesis, what affects
their subsequent action on EP4 receptor (Hawcroft et al., 2010).
Alone, PGE3 acts as a partial receptor agonist but in the presence
of its natural ligand, PGE2, it competes for the receptor and acts
as an antagonist. Importantly, HT-29 human CRC cells with EP4
overexpression (HT-29-EP4) do not produce detectable amounts
of PGE2 or PGE3 and exhibit no reaction to treatment with
EPA-FFA (Hawcroft et al., 2010).
Possibly, an even better form of delivering PUFAs are
monoacylglycerols. Morin et al. (2013) showed that this form can
be more easily absorbed than FFA. In vitro, monoacylglycerol
used to deliver docosapentaenoic acid (DPA), an intermediate
product between EPA and DHA, to CRC cell lines showed more
potent anti-proliferative and pro-apoptotic effect than either EPA
or DHA. The action of DPA was also confirmed in a mouse
xenograft model of CRC (Morin et al., 2013).
Gounaris et al. (2015) proposed another way to target
PUFA metabolism in CRC. In a mouse model of polyposis,
the administration of Zileuton (5-LO inhibitor registered for
threating asthma) resulted in markedly lowered systemic and
local lesion inflammation and led to a decrease in polyp
burden (Gounaris et al., 2015). This warrants clinical studies of
agents influencing PUFA metabolism in patients with high risk
of CRC.
Clinical Application
In humans, n-3 PUFAs have been tested as adjuvants to
standard therapy, components of nutritional treatment and
supplements for prevention in high-risk groups. Important
clinical studies from each field has been summed up in
Table 3.
When used as an addition to the treatment protocol, oral n-
3 PUFAs supplementation (600 mg/day EPA + DHA) reduced
inflammation in patients receiving chemotherapy (Mocellin
et al., 2013). The results from a metaanalysis by Mocellin
et al. (2015) supported n-3 PUFA supplementation as a way
to diminish the inflammatory state in CRC patients, either by
decreasing levels of IL-6 or CRP/albumin ratio. Moreover, Silva
et al. (2012) showed that fish oil supplementation (2 g of fish
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TABLE 3 | Recent clinical reports on n-3 PUFA as primary prevention supplements, prospective therapeutics, adjuvants to chemotherapy, nutritional
treatment, or prevention in high-risk groups.
n-3 PUFA in CRC
Condition Study design Participants Intervention Outcomes References
PRIMARY PREVENTION
Patients with diabetes, impaired
glucose tolerance or impaired fasting
glycemia
2 × 2 RCT (median
follow-up 6.2 years)
12,536 Insulin: individual regimen, n-3
PUFA: 900mg ethyl esters daily
No effect of n-3 PUFA
intervention on CRC
occurence
Bordeleau et al., 2014
ADJUVANT TO CHEMOTHERAPY
Patients with CRC in chemotherapy RCT (9 weeks of treatment) 11 2 g of fish oil/daily (600 mg/day
EPA + DHA) vs. no
supplementation
Reduced CRP/albumin
ratio
Mocellin et al., 2013
NUTRITIONAL TREATMENT
Patients with solid tumors RCT (7 days of treatment) 38 400 ml of medical food, high in
protein and leucine, enriched with
fish oil and oligosaccharides vs.
iso-caloric/iso-nitrogenous product
Reduced PGE2 levels Faber et al., 2013
Patients referred for CRC elective
surgery
Double-blind RCT (7 days of
treatment)
138 Oral nutritional supplement (2 g
EPA/day, 1 g DHA/day) vs.
standard supplement
Increase in LTB5 and
5-HEPE production,
decrease in LTB4
production by
stimulated neutrophils,
no effect on
post-operative
complications
Sorensen et al., 2014
CLINICAL TRIAL IN METASTATIC CRC
Patients undergoing liver resection
for CRC liver metastases
Double-blind RCT (median
30 days of treatment)
88 EPA-FFA 2g daily vs. placebo No difference in Ki-67
proliferative index,
better overall survival
Cockbain et al., 2014
PREVENTION IN HIGH-TISK GROUPS
Patients with FAP after colectomy RCT (6 months of treatment) 55 EPA-FFA 500mg twice daily vs.
placebo
Reduction in polyp
sizes, numbers and
global polyp burden
West et al., 2010
5-HEPE, 5-hydroxy-eicosapentaenoic acid; ASA, amino salicylic acid; CD, Crohn disease; CLA, conjugated linoleic acid; CRP, C-reactive protein; DHA, docosahexaenoic acid; EPA,
eicosapentaenoic acid; FAP, familial adenomatous polyposis; IBD, inflammatory bowel disease; IFNγ , interferon-gamma; LTB5, leukotriene B-5; PGE2, prostaglandin E2; PUFA,
polyunsaturated fatty acid; RCT, randomized controlled trial.
oil, 600mg/day EPA + DHA) prevented weight loss in patients
undergoing chemotherapy, which may influence their quality of
life and overall wellbeing. Additionally, another study by Faber
et al. (2013) proved that supplementation of EPA (600mg/day)
with DHA (300 mg/day) in medical food to patients receiving
radiotherapy effectively lowers serum levels of pro-inflammatory
mediator PGE2.
In perioperative conditions, EPA (2 g/day) and DHA
(1 g/day) in oral nutritional supplementation also showed anti-
inflammatory effects by inducing the conversion of LTB5 to LTB4
in stimulated neutrophils (Sorensen et al., 2014). Nevertheless,
the rate of surgical complications was similar between study and
control group.
In phase II clinical trials, Cockbain et al. (2014) reported a
direct effect of EPA-FFA intake on CRC cells. Patients undergoing
liver resection for CRC liver metastases were supplemented
with EPA-FFA (2 g/day) or placebo but this supplementation
did not change the Ki-67, a proliferation marker index, in
CRC. Nonetheless, the therapy was safe, well-tolerated, and
reduced tumor vascularization and improved overall survival
rate.
PUFAs as Possible Prevention in High-Risk
Groups
Age and sedentary lifestyle are established risk factors for
developing CRC (Bonnington and Rutter, 2016). There are also
hereditary conditions, such as familial adenomatous polyposis
(FAP) which are associated with high number of possibly-
malignant polyps (Brosens et al., 2015). In general population,
detection of pre-cancerous polyps in colonoscopy is a risk factor
for the development of CRC later in life (Bonnington and
Rutter, 2016). All these patients are possible target groups for
intervention with PUFAs. In patients with FAP, a 6-month-
long supplementation with 2 g of EPA-FFA daily reduced the
number of polyps by 22.4% and their size (diameter) by
29.8%. It also prevented the rise in global polyp burden, when
compared with the non-supplemented group (+0.09 vs. −0.34,
difference 0.42, statistically significant) (West et al., 2010).
Recently, a multicenter double-blinded, placebo-controlled trial
was conducted on patients with colonoscopy-detected polyps
or aberrant crypti focci (ACF), supplemented with EPA 900mg
or placebo thrice daily for 1 month (Higurashi et al., 2012).
The endpoints included formation of ACF, cell-proliferative
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TABLE 4 | Summary of ongoing and recently completed clinical trials.
Status; ClinicalTrials.gov
Identifier
Title Study design Indication Diet and
intervention
Primary endpoint
Recruiting; NCT02534389 Fish oil supplement combined
with neoadjuvant
chemoradiation for locally
advanced rectal cancer
I, R, OP Rectal neoplasm Omega-3 fish oil, 2.4 g
of EPA + DHA vs. no
intervention
Effects of daily consumption of
2.4 g of EPA + DHA for adults
with rectal adenocarcinoma in
neoadjuvant chemoradiation
treatment on Glasgow
Prognostic Score
Active, not recruiting;
NCT02699047
Gastrointestinal cancer: effects
of the fish oil intake on
nutritional status, quality of life
and immune and metabolic
outcomes
I, R, DB GI cancer, CRC,
stomach cancer
Encapsulated fish oil
vs. encapsulated
olive oil
Change in quality of life,
inflammatory response, body
weight, body mass index,
serum C-reactive protein,
tumor markers (CEA, CA-19),
serum albumin, survival and
others
Active, not recruiting;
NCT01661764
Fatty acid desaturase activity,
fish oil and colorectal cancer
prevention
I, R, DB Adenomatous
colorectal polyps
EPA and DHA vs. oleic
acid
Rectal epithelial cell,
proliferation, rectal epithelial
cell apoptosis
Recruiting; NCT02179372 Modulation of fecal calprotectin
by eicosapentaenoic free fatty
acid in inflammatory bowel
diseases
I, R, DB UC, CD EPA vs. MCFA
(placebo)
Changes in FC levels
Completed; NCT02069561 Effects of eicosapentaenoic
acid on molecular,
metabonomics and intestinal
microbiota changes, in
subjects with long-standing
inflammatory bowel disease
I, non-R, OP UC EPA vs. no
intervention
Changes in RNA profiles, DNA
methylation profiles, in cell
proliferation and apoptosis
Completed; NCT02349594 Modulation of immune function
by parenteral fish oil in patients
with Crohn’s disease and high
inherent tumor necrosis
factor-alpha production: a
randomized, single blinded,
cross-over study
I, R, SB CD Omegaven 10% vs.
Intralipid 20%
Change in TNF-α production
(pg/ml)
CA-19, cancer antigen 19; CD, Crohn’s disease; CEA, carcinoembryonic antigen; CRC, colorectal cancer; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FC, fecal
calprotectin; GI, gastrointestinal; MCFA, medium chain fatty acid; UC, ulcerative colitis.
Study design: DB, double blinded; I, interventional; non-R, non randomized; OP, open label; R, randomized; SB, single blinded.
and cell-apoptotic activity in colorectal polyps and normal
mucosa. No results have been published so far; however, the
trial has been registered in UMIN-CTR Search Clinical Trials as
UMIN000008172.
Currently, there are also two randomized clinical trials
evaluating a possible use of PUFA in patients at increased
risk of CRC. The former investigates the effect of EPA and
aspirin in a 2 × 2 factorial randomized controlled trial on
colorectal adenoma (Hull et al., 2013). The target group includes
patients at increased risk (55–74 y.o., >5 adenomas or >3
adenomas with at list one >10mm diam. found at the first
complete screening colonoscopy). The endpoints of the 12-
month supplementation with EPA include, among others, the
number of patients with one or more adenomas at surveillance
colonoscopy, the number of advanced adenomas and the number
of patients reclassified into intermediate risk (Current Control
Trials ISRCTN05926847). The second clinical trial is conducted
by Harvey Murff from Vanderbilt University (ClinicalTrials.gov
Identifier: NCT01661764). It aims to recruit 150 participants
with recently identified adenomatous polyps and conduct a
6-month double blind 3 × 2 factorial randomized controlled
trial. The study will assess effects of fish oil supplementation
in patients with three different polymorphisms in fatty acid
desaturase 1 (FAD1) gene. FAD1 converts LA to AA and its
activity determines the levels of AA in tissues. In individuals with
inherently lower activity of FAD1, AA levels are substantially
lower. The trial will evaluate the efficacy of fish oil supplements
on rectal epithelial cell proliferation indexes (measured by Ki-
67 labeling) and markers of rectal crypt apoptosis. Moreover,
it will provide an insight whether the supplementation is more
beneficial in patients with specified genotype. The completion
date of this study is due December 2016. Our search also revealed
other trials investigating the effect of PUFAs supplementation
on clinical course of CRC and IBD; they are summarized in
Table 4.
CONCLUSIONS
Polyunsaturated fatty acids (PUFAs) are an important group
of bioactive lipids with pleiotropic effects in the organism.
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They affect immunity, inflammation and motility of the GI
tract. Their usefulness was proven in FGIDs, in which PGE1-
derived lubiprostone effectively alleviates the hallmark symptoms
of IBS-C and CIC. In IBD and CRC, the potential of
PUFAs is recognized but not fully utilized. When it comes to
inflammation, the spotlight is currently on n-3 PUFAs, although
AA-derived endocannabinoids also provide a promising target
for pharmacological interventions. In CRC, the main focus
is solely on n-3 PUFAs because of their inflammation- and
immune-modulating properties. EPA and DHA are potentially
useful as adjuvants to chemotherapy and possibly for CRC
prevention in high-risk groups.
Metabolites of PUFAs also exert potent biological effects, more
specific than FA themselves and thus should be of interest to
pharmaceutical industry. EPA- and DHA-derived substances like
Rvs or less known families of PGs could be useful as anti-
inflammatory drugs. Finally, liposome-encapsulated n-3 PUFAs
not only target specifically inflammatory sites e.g., IBD-related
lesions or tumor mass, but can also be tracked in the human
body. These modern drug delivery methods may be the key to
unlocking true medical potential of PUFAs.
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